Drug delivery in acute myeloid leukemia
Standard
Drug delivery in acute myeloid leukemia. / Kohlschütter, Johannes; Michelfelder, Stefan; Trepel, Martin.
in: EXPERT OPIN DRUG DEL, Jahrgang 5, Nr. 6, 06.2008, S. 653-63.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Drug delivery in acute myeloid leukemia
AU - Kohlschütter, Johannes
AU - Michelfelder, Stefan
AU - Trepel, Martin
PY - 2008/6
Y1 - 2008/6
N2 - BACKGROUND: Acute myeloid leukemia was among the first malignancies to be cured by drug therapy alone, but overall survival rates remain unsatisfactory and have changed little over the past 20 years. Conventional chemotherapeutic regimens, which almost invariably include cytarabine and anthracyclines, are untargeted, and more specific therapies are needed.OBJECTIVE: We have chosen acute myeloid leukemia as a disease prototype to review established and novel targeted approaches in leukemia treatment.METHODS: Our selection of the reviewed literature focused on drug delivery aspects.CONCLUSION: While the toxicity profile of chemotherapeutics has been improved by liposomal formulations and antibody conjugation for leukemia-directed uptake, their efficacy has probably not changed significantly. Drugs with an alternative mode of action, including kinase inhibitors, hold great promise. Further improvements may result from the characterization of novel acute myeloid leukemia (AML) cell surface receptors and of leukemic stem cells, as well as from the design of leukemia-targeted gene therapy vectors.
AB - BACKGROUND: Acute myeloid leukemia was among the first malignancies to be cured by drug therapy alone, but overall survival rates remain unsatisfactory and have changed little over the past 20 years. Conventional chemotherapeutic regimens, which almost invariably include cytarabine and anthracyclines, are untargeted, and more specific therapies are needed.OBJECTIVE: We have chosen acute myeloid leukemia as a disease prototype to review established and novel targeted approaches in leukemia treatment.METHODS: Our selection of the reviewed literature focused on drug delivery aspects.CONCLUSION: While the toxicity profile of chemotherapeutics has been improved by liposomal formulations and antibody conjugation for leukemia-directed uptake, their efficacy has probably not changed significantly. Drugs with an alternative mode of action, including kinase inhibitors, hold great promise. Further improvements may result from the characterization of novel acute myeloid leukemia (AML) cell surface receptors and of leukemic stem cells, as well as from the design of leukemia-targeted gene therapy vectors.
KW - Antibodies, Monoclonal
KW - Antigens, CD
KW - Antigens, Differentiation, Myelomonocytic
KW - Antineoplastic Agents
KW - Drug Delivery Systems
KW - Genetic Therapy
KW - Humans
KW - Integrin alpha4beta1
KW - Leukemia, Myeloid, Acute
KW - Liposomes
KW - Neoplastic Stem Cells
KW - Sialic Acid Binding Ig-like Lectin 3
KW - Journal Article
KW - Review
U2 - 10.1517/17425247.5.6.653
DO - 10.1517/17425247.5.6.653
M3 - SCORING: Review article
C2 - 18532921
VL - 5
SP - 653
EP - 663
IS - 6
ER -